Kisqali

Q: How much longer do you live on Kisqali?

<p>The median ove<a href="https://www.withpower.com/clinical-trials/ra">ra</a>ll survival rate for those taking KISQALI was not reached at the 39 month check-in, as opposed to the 40 months check-in for those taking placebo. Results at the 56-month observational check-in showed that the median overall survival rate for those taking KISQALI in combination with fulvestrant was 53.7 months, as opposed to 41.5 months for those taking placebo and fulvestrant.</p>

Postmenopause, Breast, Metastatic Breast Cancer

Treatment

3 FDA approvals

20 Active Studies for Kisqali

Treatment for

Postmenopause

What is Kisqali

RibociclibThe Generic name of this drug

Treatment SummaryRibociclib is a medication used to slow the growth of cancer cells. It works by targeting proteins called cyclin-dependent kinase 4 and 6 (CDK4/6) which control how fast cancer cells divide. By blocking these proteins, ribociclib helps prevent cancer cells from reproducing uncontrollably and spreading. The drug was approved by the FDA in 2017 and is known by the brand name Kisqali.

Kisqaliis the brand name

Kisqali Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Kisqali

Ribociclib

2017

Approved as Treatment by the FDA

Ribociclib, commonly known as Kisqali, is approved by the FDA for 3 uses like Postmenopause and Breast .

Postmenopause

Used to treat Postmenopausal in combination with null

Breast

Used to treat Advanced Breast Cancer in combination with null

Metastatic Breast Cancer

Used to treat Metastatic Breast Cancer in combination with null

Effectiveness

How Kisqali works in the bodyRibociclib is a drug used to treat cancer by blocking a specific type of enzyme found in some types of tumors. This enzyme, called cyclin-dependent kinase 4 and 6 (CDK4/6), helps the tumor to grow. Ribociclib is able to stop this enzyme from working, which prevents the growth of the tumor. It also prevents the tumor cells from reproducing, which helps to keep the tumor from spreading.

When to interrupt dosage

The recommended measure of Kisqali is contingent upon the ascertained condition, for example Metastatic Breast Cancer, Breast and Postmenopause. The dosage likewise vacillates as per the approach of delivery (e.g. Oral or Tablet, film coated) specified in the table beneath.

Condition

Dosage

Administration

Metastatic Breast Cancer

200.0 mg,

Oral, Tablet, film coated, Kit; Tablet; Tablet, film coated - Oral, , Tablet, Kit; Tablet; Tablet, film coated, Tablet - Oral, Tablet, film coated - Oral

Breast

200.0 mg,

Oral, Tablet, film coated, Kit; Tablet; Tablet, film coated - Oral, , Tablet, Kit; Tablet; Tablet, film coated, Tablet - Oral, Tablet, film coated - Oral

Postmenopause

200.0 mg,

Oral, Tablet, film coated, Kit; Tablet; Tablet, film coated - Oral, , Tablet, Kit; Tablet; Tablet, film coated, Tablet - Oral, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Kisqali.

Common Kisqali Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Ribociclib.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Ribociclib.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Ribociclib.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Ribociclib.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Ribociclib.

Kisqali Novel Uses: Which Conditions Have a Clinical Trial Featuring Kisqali?

94 active clinical trials are currently assessing the potential of Kisqali to provide therapeutic benefit in Metastatic Breast Cancer, Postmenopausal Women and Breast Diseases.

Condition

Clinical Trials

Trial Phases

Postmenopause

6 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Breast

16 Actively Recruiting

Phase 2, Phase 1, Phase 3

Metastatic Breast Cancer

82 Actively Recruiting

Phase 2, Not Applicable, Phase 3, Phase 1, Phase 4

Kisqali Reviews: What are patients saying about Kisqali?

5Patient Review

12/10/2021

Kisqali for Hormone Receptor (HR)-Positive, HER2-Negative Advanced Breast Cancer in Woman

I've been using this treatment since May 2017 and it's working great! I have experienced some hair thinning and fatigue, but those are the only side effects so far.

5Patient Review

8/20/2019

Kisqali for Hormone Receptor (HR)-Positive, HER2-Negative Advanced Breast Cancer in Woman

Kisqali has been working great for me- I've had seven cycles of it and my PET/CT scan shows no cancer!

Patient Q&A Section about kisqali

What is the drug Kisqali used for?

"KISQALI® is a prescription medicine that is used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer). The cancer must have gotten worse or has spread to other parts of the body (metastatic) in order for KISQALI® to be prescribed. It is usually taken in combination with an aromatase inhibitor as the first hormonal based therapy for postmenopausal women or with fulvestrant." - Anonymous Online Contributor

Unverified Answer

Is Kisqali a chemotherapy?

"KISQALI is not a chemotherapeutic drug, but a targeted therapy that inhibits substances that contribute to cancer cell growth. Targeted therapies can harm both cancerous and healthy cells." - Anonymous Online Contributor

Unverified Answer

How much longer do you live on Kisqali?

"The median overall survival rate for those taking KISQALI was not reached at the 39 month check-in, as opposed to the 40 months check-in for those taking placebo. Results at the 56-month observational check-in showed that the median overall survival rate for those taking KISQALI in combination with fulvestrant was 53.7 months, as opposed to 41.5 months for those taking placebo and fulvestrant." - Anonymous Online Contributor

Unverified Answer

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.